CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice.

摘要: Background and objective Targeted drug delivery of nanoparticles decorated with site-specific recognition ligands is considerable interest to minimize cytotoxicity chemotherapeutics in the normal cells. The study was designed develop CD-340 antibody-conjugated polylactic-co-glycolic acid (PLGA) loaded a highly water-soluble potent anticancer drug, doxorubicin (DOX), specifically deliver entrapped DOX breast cancer Methods showed how incorporate hydrophobic PLGA (85:15) based matrix which otherwise shows poor loading due leaching effect. optimized formulation covalently conjugated anti-human epidermal growth factor receptor-2 (HER2) antibody (CD-340). Surface conjugation ligand assessed by flow cytometry, confocal microscopy, gel electrophoresis. Selectivity experimental were tested on human cells SKBR-3, MCF-7, MDA-MB-231. Both CD-340-conjugated unconjugated undergone vitro vivo characterization. Result Higher level incorporation (8.5% W/W), effect seen this method. In HER2-overexpressing tumor xenograft model, radiolabeled preferentially more accumulation area when compared treatments one or other control groups mice. potential reduction cardiac toxicity mice, prominent side-effect drug. Conclusion conclusion, containing delivered encapsulated reduced apoptosis. Site-specific neoplastic did not affect drastic DOX-related cardiotoxicity.